Nonsignificant Survival Benefit Seen for Dabrafenib, Trametinib in Melanoma
Consistent survival benefit seen across several prespecified subgroups, including those with a BRAF V600E mutation
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.